These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6836557)

  • 1. Carnitine depletion as a probable cause of hyperlipidemia in uremic patients on maintenance hemodialysis.
    Maebashi M; Imamura A; Yoshinaga K; Sato T; Funyu T; Ishidoya Y; Hirayama N
    Tohoku J Exp Med; 1983 Jan; 139(1):33-42. PubMed ID: 6836557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carnitine deficiency induced during hemodialysis and hyperlipidemia: effect of replacement therapy.
    Bertoli M; Battistella PA; Vergani L; Naso A; Gasparotto ML; Romagnoli GF; Angelini C
    Am J Clin Nutr; 1981 Aug; 34(8):1496-500. PubMed ID: 7270472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis.
    Guarnieri GF; Ranieri F; Toigo G; Vasile A; Ciman M; Rizzoli V; Moracchiello M; Campanacci L
    Am J Clin Nutr; 1980 Jul; 33(7):1489-92. PubMed ID: 7395772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperlipidemia in uremic children: response to peritoneal dialysis and hemodialysis.
    Berger M; James GP; Davis ER; Jasper PM; Brouhard BH; Travis LB; Cunningham RJ
    Clin Nephrol; 1978 Jan; 9(1):19-24. PubMed ID: 343952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carnitine depletion during chronic hemodialysis: effect of substitution on free carnitine plasma levels.
    Broquet PE; Von Moos C; Frei J; Gobelet C; Wauters JP
    Adv Exp Med Biol; 1987; 223():287-90. PubMed ID: 3447448
    [No Abstract]   [Full Text] [Related]  

  • 6. High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis.
    Weschler A; Aviram M; Levin M; Better OS; Brook JG
    Nephron; 1984; 38(2):120-4. PubMed ID: 6472539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-carnitine and platelet aggregation in uremic patients subjected to hemodialysis.
    Bellinghieri G; Savica V; Barbera CM; Ricciardi B; Egitto M; Torre F; Valentini G; D'Iddio S; Bagiella E; Mallamace A
    Nephron; 1990; 55(1):28-32. PubMed ID: 2141109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients.
    Elisaf M; Bairaktari E; Katopodis K; Pappas M; Sferopoulos G; Tzallas C; Tsolas O; Siamopoulos KC
    Am J Nephrol; 1998; 18(5):416-21. PubMed ID: 9730566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dialysate composition on the lipid response to L-carnitine supplementation.
    Zilleruelo G; Novak M; Hsia SL; Goldberg R; Abitbol C; Monkus E; Strauss J
    Kidney Int Suppl; 1989 Nov; 27():S259-63. PubMed ID: 2699997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carnitine nutriture of dialysis patients.
    Borum PR; Taggart EM
    J Am Diet Assoc; 1986 May; 86(5):644-7. PubMed ID: 3700927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of long-term treatment with L-carnitine on dyslipemia in hemodialysis patients].
    Dionisio P; Bergia R; Caramello E; Graziola M; Valenti M; Bajardi P; Barbera L; Voglino F
    Minerva Med; 1985 Feb; 76(6):229-34. PubMed ID: 3974937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of L-carnitine on arrhythmias during hemodialysis.
    Suzuki Y; Narita M; Yamazaki N
    Jpn Heart J; 1982 May; 23(3):349-59. PubMed ID: 6178854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol.
    Vacha GM; Giorcelli G; Siliprandi N; Corsi M
    Am J Clin Nutr; 1983 Oct; 38(4):532-40. PubMed ID: 6624695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma post-heparin lipolytic activity and triglyceride clearance in uremic and hemodialysis patients and renal allograft recipients.
    Ibels SL; Reardon MF; Nestel PJ
    J Lab Clin Med; 1976 Apr; 87(4):648-58. PubMed ID: 775004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of carnitine in modulating acute-phase protein synthesis in hemodialysis patients.
    Bellinghieri G; Santoro D; Calvani M; Savica V
    J Ren Nutr; 2005 Jan; 15(1):13-7. PubMed ID: 15648000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective deficiency of hepatic triglyceride lipase in uremic patients.
    Mordasini R; Frey F; Flury W; Klose G; Greten H
    N Engl J Med; 1977 Dec; 297(25):1362-6. PubMed ID: 200841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis: the relative pathogenetic roles of triglyceride production and triglyceride removal.
    Chan MK; Varghese Z; Persaud JW; Baillod RA; Moorhead JF
    Clin Nephrol; 1982 Apr; 17(4):183-90. PubMed ID: 7075035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-carnitine addition to dialysis fluid. A therapeutic alternative for hemodialysis patients.
    Vacha GM; Giorcelli G; d'Iddio S; Valentini G; Bagiella E; Procopio A; di Donato S; Ashbrook D; Corsi M
    Nephron; 1989; 51(2):237-42. PubMed ID: 2915763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cholesterol binding reserve and high density lipoprotein cholesterol in patients on maintenance hemodialysis.
    Perez GO; Hsia SL; Christakis G; Burr J
    Horm Metab Res; 1980 Sep; 12(9):449-54. PubMed ID: 7429416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.